FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2273666069> ?p ?o ?g. }

• W2273666069 endingPage "7" @default.
• W2273666069 startingPage "1213" @default.
• W2273666069 abstract "On the basis of observation of the effects on glucose metabolism of estrogens and progestins administered alone or in combination, it is believed that deterioration of glucose tolerance in the 1st trimester of oral contraceptive (OC) use is due to the synthetic estrogen, while hyperinsulinism after the 6th month of use is due to the progestin component. Either the estrogen-induced deterioration of glucose tolerance or the progestin-induced insulin resistence may lead to poor glucose tolerance or diabetes in predisposed individuals. The early deterioration of glucose tolerance with synthetic estrogens is probably due to a direct action of estrogens on the pancreas, where specific estrogen receptors have been identified, but the regression of this effect has not been explained. The reduction of fasting glucose levels by synthetic estrogens is due to a reduction of glucogenolysis and of gluconeogenesis with an increase of hepatic gluconeogenesis. These 3 effects may be explained by the action of estrogens on insulin and glucagon: estrogens inhibit the secretion of glucagon induced by arginine, an effect not obtained by progestins. A daily injection of estradiol for 6 weeks in overiectomized rats results in a lowered level of insulin and glucagon with an elevated insulin/glucagon ratio in the portal vein; this results in a decline in gluconeogenesis with a particular decline in phospho-enol-pyruvate-carboxy-kinase activity. Progestins on the other hand augment insulin and glucagon secretion without modifying their ratio in the portal vein. Hyperinsulinism in the basal state and after stimulation is observed in women using combined OCs or progestins only, whether or not there is a deterioration of glucose tolerance. The effect appears after 3 months of use and continues as long as OCs are used. This hyperinsulinism is due to a hypersecretion and not to a diminution in degradation of insulin. The insulin/glucose ratio is elevated; the hypersecretion of insulin compensates for a lowered peripheral sensitivity to the hormone. Pill-induced insulin resistence is comparable to that of pregnancy. Although all progestins used in contraception induce insulin resistence with hyperinsulinism, the effect is more marked with 19 nortestosterone derivatives than with those of 17 alpha hydroxyprogesterone, because of the structural similarity of 19 norsteroids to anabolic androgens. 2 arguments suggest a potentialization of the effects of progestins by the estrogens in combined OCs: estrogens diminish the biliary flow and may therefore diminish progesterone secretion, and progestin catabolism is diminished by estrogens. Theories have been proposed to explain the diabetogenic effect of combined OCs through indirect mechanisms involving cortisol, growth hormone, or tryptophane metabolism." @default.
• W2273666069 created "2016-06-24" @default.
• W2273666069 creator A5072589926 @default.
• W2273666069 date "1985-12-01" @default.
• W2273666069 modified "2023-09-23" @default.
• W2273666069 title "[Oral contraception and carbohydrate metabolism--the physiopathological explanation]." @default.
• W2273666069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12267513" @default.
• W2273666069 hasPublicationYear "1985" @default.
• W2273666069 type Work @default.
• W2273666069 sameAs 2273666069 @default.
• W2273666069 citedByCount "0" @default.
• W2273666069 crossrefType "journal-article" @default.
• W2273666069 hasAuthorship W2273666069A5072589926 @default.
• W2273666069 hasConcept C126322002 @default.
• W2273666069 hasConcept C134018914 @default.
• W2273666069 hasConcept C17093226 @default.
• W2273666069 hasConcept C20904676 @default.
• W2273666069 hasConcept C2777164284 @default.
• W2273666069 hasConcept C2777368190 @default.
• W2273666069 hasConcept C2777391703 @default.
• W2273666069 hasConcept C2778563252 @default.
• W2273666069 hasConcept C2779306644 @default.
• W2273666069 hasConcept C62231903 @default.
• W2273666069 hasConcept C71924100 @default.
• W2273666069 hasConcept C86803240 @default.
• W2273666069 hasConceptScore W2273666069C126322002 @default.
• W2273666069 hasConceptScore W2273666069C134018914 @default.
• W2273666069 hasConceptScore W2273666069C17093226 @default.
• W2273666069 hasConceptScore W2273666069C20904676 @default.
• W2273666069 hasConceptScore W2273666069C2777164284 @default.
• W2273666069 hasConceptScore W2273666069C2777368190 @default.
• W2273666069 hasConceptScore W2273666069C2777391703 @default.
• W2273666069 hasConceptScore W2273666069C2778563252 @default.
• W2273666069 hasConceptScore W2273666069C2779306644 @default.
• W2273666069 hasConceptScore W2273666069C62231903 @default.
• W2273666069 hasConceptScore W2273666069C71924100 @default.
• W2273666069 hasConceptScore W2273666069C86803240 @default.
• W2273666069 hasIssue "12" @default.
• W2273666069 hasLocation W22736660691 @default.
• W2273666069 hasOpenAccess W2273666069 @default.
• W2273666069 hasPrimaryLocation W22736660691 @default.
• W2273666069 hasRelatedWork W1760162727 @default.
• W2273666069 hasRelatedWork W1972238624 @default.
• W2273666069 hasRelatedWork W2074497389 @default.
• W2273666069 hasRelatedWork W2110582111 @default.
• W2273666069 hasRelatedWork W2131745238 @default.
• W2273666069 hasRelatedWork W2137407928 @default.
• W2273666069 hasRelatedWork W2273666069 @default.
• W2273666069 hasRelatedWork W227807220 @default.
• W2273666069 hasRelatedWork W2415781505 @default.
• W2273666069 hasRelatedWork W2418926412 @default.
• W2273666069 hasVolume "13" @default.
• W2273666069 isParatext "false" @default.
• W2273666069 isRetracted "false" @default.
• W2273666069 magId "2273666069" @default.
• W2273666069 workType "article" @default.